Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04927455
Other study ID # CHUBX 2020/35
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 16, 2021
Est. completion date April 2023

Study information

Verified date February 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In France, alcohol consumption is the second most common cause of so-called preventable cancers after tobacco. Since 2014, in the "Provence-Alpes-Côte d'Azur" (PACA) region, the association Santé! has been developing an innovative intervention to support people suffering from alcohol-related addiction. This intervention, called IACA! must therefore be evaluated on a larger scale before conclusions about its effectiveness can be drawn from a comparative trial. This evaluation requires significant human and material resources. It is therefore recommended to first assess the transferability of IACA! in other care centers in a pilot study.


Description:

In France, 11% of cancers in men and 4.5% of cancers in women are attributed to alcohol consumption. It is the second leading cause of so-called preventable cancers, accounting for 28,000 alcohol-related cancers out of 352,000 new cases of cancer affecting annually adults (over 30 years of age). Overall, alcohol is among the top 3 factors contributing to Disability-Adjusted life year (DALYs) in France in 2017. Some cancer risks can be quantified as early as one drink a day (oesophagus, oral cavity, pharynx and breast in women). However, the risks associated with alcohol consumption remain influenced by the quantities consumed. There is therefore an interest, particularly for consumers of the largest quantities, in reducing the quantities consumed. In Europe, while people who drink more than 60 g/d of alcohol for men and 40 g/d for women are estimated to represent only 16.1% of the population for men and 9.3% for women, they represent 87% and 82% of alcohol-related morbidity and mortality respectively. Subjects with addiction (or substance use disorders) have an increased risk of social harm (1.5 to 3 times that of alcohol users without addiction), a higher mortality (1.4 to 6.5 compared to the general population) with a life expectancy of 9 to 20 years shorter than that of the general population. Moreover, even if the quantities consumed are not a valid individual diagnostic criterion, studies show a strong association between the quantity consumed and the diagnosis of addiction. Finally, some studies suggest that the prevalence of secondary harm from alcohol use follows an exponential curve as a function of alcohol consumption. Since 2014, in the PACA region, the association Santé! has been developing an intervention to support people suffering from alcohol-related addiction. This intervention, called IACA! (Integrating and supporting alcohol consumption), differs from the support provided during rehabilitation cures and aims to: fight against discrimination and exclusion of people who drink alcohol, re-engage these individuals in the care process (because they have generally left it) by using the appropriate levers, promote well-being, improve quality of life and recovery and support the recovery in control of consumption. Thus, IACA!, through its philosophy and implementation, is based both on the risk reduction approach historically deployed with drug users and on the recovery approach, developed in the field of mental health. The first one-year results of this program were promising since, of 17 people who received the intervention, all had a social or health benefit, 13 of whom were associated with stabilization (n=4), reduction (n=7) or cessation (n=2) of alcohol use. These promising results must therefore be evaluated on a larger scale before conclusions about its effectiveness can be drawn from a comparative trial. This type of evaluation requires significant human and material resources. It is therefore recommended to first assess in the field: 1) the conditions under which such an intervention is deployed in other centres (adaptations implemented by other centres to deploy IACA! for example, without distorting the intervention), 2) the acceptability and feasibility of the intervention in other centres (are the human and material resources on site sufficient for the successful deployment of the intervention?), 3) the acceptability and feasibility of the large-scale evaluation envisaged.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date April 2023
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria common to the 3 populations: - Over 18 years of age - whatever the gender - Non-opposition to participate Inclusion criteria for professionals from centers implementing IACA! : Concerning professionals in contact with the patients: - Having been trained at IACA! - Working in the centers participating in the implementation of IACA! Concerning the persons in charge of the centers : These professionals are those who have participated in the deployment of the IACA! method in their centers Criteria for the inclusion of health professionals ! Participating or having recently participated in the implementation of IACA! Exclusion Criteria: The beneficiaries will be excluded if they have a severe somatic or psychiatric pathology that is incompatible with understanding the assessment tools; difficulty understanding and/or writing French; if they are unreachable by telephone, if they are participating in another research project with an ongoing exclusion period, if they are placed under court protection and if they are pregnant.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CH Perrens - Equipe Addiction Bordeaux
France MéRISP - Université U1219 Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

References & Publications (2)

Cambon L, Minary L, Ridde V, Alla F. Transferability of interventions in health education: a review. BMC Public Health. 2012 Jul 2;12:497. doi: 10.1186/1471-2458-12-497. Review. — View Citation

Thabane L, Cambon L, Potvin L, Pommier J, Kivits J, Minary L, Nour K, Blaise P, Charlesworth J, Alla F; Discussion Panel. Population health intervention research: what is the place for pilot studies? Trials. 2019 May 30;20(1):309. doi: 10.1186/s13063-019-3422-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of alcohol use 12 months after the start of IACA
Secondary Utility dimension of viability - alcohol consumption Average number of units of alcohol consumption in the past 30 days Baseline (M0)
Secondary Utility dimension of viability - alcohol consumption Average number of units of alcohol consumption in the past 30 days 3 months (M3)
Secondary Utility dimension of viability - alcohol consumption Average number of units of alcohol consumption in the past 30 days 6 months (M6)
Secondary Utility dimension of viability - alcohol consumption Average number of units of alcohol consumption in the past 30 days 9 months (M9)
Secondary Utility dimension of viability - alcohol consumption Average number of units of alcohol consumption in the past 30 days 12 months (M12)
Secondary Utility dimension of viability - craving Craving: average frequency and intensity in the last 30 days Baseline (M0)
Secondary Utility dimension of viability - craving Craving: average frequency and intensity in the last 30 days 3 months (M3)
Secondary Utility dimension of viability - craving Craving: average frequency and intensity in the last 30 days 6 months (M6)
Secondary Utility dimension of viability - craving Craving: average frequency and intensity in the last 30 days 9 months (M9)
Secondary Utility dimension of viability - craving Craving: average frequency and intensity in the last 30 days 12 months (M12)
Secondary Utility dimension of viability - severity Severity score for addictive substances and behaviors Baseline (M0)
Secondary Utility dimension of viability - severity Severity score for addictive substances and behaviors 3 months (M3)
Secondary Utility dimension of viability - severity Severity score for addictive substances and behaviors 6 months (M6)
Secondary Utility dimension of viability - severity Severity score for addictive substances and behaviors 9 months (M9)
Secondary Utility dimension of viability - severity Severity score for addictive substances and behaviors 12 months (M12)
Secondary Utility dimension of viability - disorders Presence of alcohol and other substance use disorders (past 12 months and past) Baseline (M0)
Secondary Utility dimension of viability - disorders Presence of alcohol and other substance use disorders (past 12 months and past) 3 months (M3)
Secondary Utility dimension of viability - disorders Presence of alcohol and other substance use disorders (past 12 months and past) 6 months (M6)
Secondary Utility dimension of viability - disorders Presence of alcohol and other substance use disorders (past 12 months and past) 9 months (M9)
Secondary Utility dimension of viability - disorders Presence of alcohol and other substance use disorders (past 12 months and past) 12 months (M12)
Secondary Utility dimension of viability - Other substances Number of days of use of other substances/behaviours in the past 30 days Baseline (M0)
Secondary Utility dimension of viability - Other substances Number of days of use of other substances/behaviours in the past 30 days 3 months (M3)
Secondary Utility dimension of viability - Other substances Number of days of use of other substances/behaviours in the past 30 days 6 months (M6)
Secondary Utility dimension of viability - Other substances Number of days of use of other substances/behaviours in the past 30 days 9 months (M9)
Secondary Utility dimension of viability - Other substances Number of days of use of other substances/behaviours in the past 30 days 12 months (M12)
Secondary Utility dimension of viability - Inventory Inventory of medical, psychosocial and psycho-educational contacts in the last 30 days Baseline (M0)
Secondary Utility dimension of viability - Inventory Inventory of medical, psychosocial and psycho-educational contacts in the last 30 days 3 months (M3)
Secondary Utility dimension of viability - Inventory Inventory of medical, psychosocial and psycho-educational contacts in the last 30 days 6 months (M6)
Secondary Utility dimension of viability - Inventory Inventory of medical, psychosocial and psycho-educational contacts in the last 30 days 9 months (M9)
Secondary Utility dimension of viability - Inventory Inventory of medical, psychosocial and psycho-educational contacts in the last 30 days 12 months (M12)
Secondary Utility dimension of viability - QoL Quality of life Baseline (M0)
Secondary Utility dimension of viability - QoL Quality of life 3 months (M3)
Secondary Utility dimension of viability - QoL Quality of life 6 months (M6)
Secondary Utility dimension of viability - QoL Quality of life 9 months (M9)
Secondary Utility dimension of viability - QoL Quality of life 12 months (M12)
Secondary Conditions of transferability Conditions of transferability linked to the characteristics of the stakeholders and the context: contextual conditions for success within the centres, the characteristics of professionals and patients influencing outcomes 9 to 12 months (M9 to M12)
Secondary Viability and implementation Implementation of IACA! (process, resources, activities) including the respect of IACA! success principles (skills, postures) 6 to 12 months (M6 to M12)
Secondary Viability and utility "utility" dimension (as a complement to the secondary criteria) of viability through the recovery mechanisms identified as successful mental health recovery 6 to 12 months (M6 to M12)
Secondary Viability and affordability Affordability for professionals and beneficiaries (financial, geographical, social and cultural levers and brakes of the intervention) 6 to 12 months (M6 to M12)
Secondary Viability and evaluability Evaluability of IACA: carrying out this evaluation, the availability of professionals and beneficiaries to answer questionnaires and interviews, missing data in the questionnaires etc. 6 to 12 months (M6 to M12)
Secondary Viability and adaptability Adaptability of IACA! (integration of the action into the context and the current organisation of the centres) 6 to 12 months (M6 to M12)
Secondary Viability and acceptability Acceptability of IACA! by professionals and beneficiaries 6 to 12 months (M6 to M12)
Secondary Feasibility study capacity The centres' capacity for inclusion (eligibility, recruitment rate, refusal rate) 12 months (M12)
Secondary Feasibility study complicance The compliance rates; understanding, acceptability and feasibility of study questionnaires and data collection tools; 12 months (M12)
Secondary Feasibility study ressources The ressources required (time required to complete all study forms, professional/centre capacity, etc.) 12 months (M12)
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2